Guardant Health, Inc.

NASDAQ:GH

Medical - Diagnostics & Research

Healthcare
$145.14 +2.07%

+$2.67 today

Market cap
$19.64B
Beta
1.62
P/E (TTM)
-39.9
EPS (TTM)
-$3.30
52W Low $40.35High $135.00

Volume 1.50M

Average 2.21M

GH Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Guardant Health, Inc.NASDAQ: GH

Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026

Capital expenditures grows, but more slowly than its trailing trend

Q3 FY2026 capital expenditures of $13.48M (cash outflow) rose 30.2% year over year, behind the +49.2% change in trailing-twelve-month capital expenditures. Sequentially, it rose 14.6% from the prior quarter. Over 3 fiscal years it compounded at -14.6% a year.

Context

  • Capital expenditures amounted to 4.9% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +30.2% toward the trailing-twelve-month pace of +49.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$13.48M+14.6% QoQ
Last fiscal yearDec 2025
-$48.31M+37.7% YoY
LTMSep 2026
-$58.67M+49.2% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.2%——
1 year+37.7%——
3-year CAGR-14.6%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(48.31M) USD
Year-over-year change
-37.7%

Capital Expenditures vs competitors

How GH compares with its peers on the latest reported figures

  • GH's LTM Sep 2026 capital expenditures of $58.67M is the 2nd largest of the 10 companies compared; the peer median is $23.06M.
  • Its year-over-year change of +49.2% is the 3rd highest of 9, against a peer median of -16.3%.
  • Capital expenditures amounts to 4.6% of revenue for GH, versus a peer median of 3.8%.
GH Competitors Peer median
Capital Expenditures for GH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$156.54M +90.6%+30.6%5.8%
GHGuardant Health, Inc.LTM Sep 2026$58.67M +49.2%-14.6%4.6%
CSTLCastle Biosciences, Inc.LTM Mar 2026$43.74M +82.9%+85.6%12.9%
NEONeoGenomics, Inc.LTM Jun 2026$29.4M -11.5%-4.4%3.8%
MYGNMyriad Genetics, Inc.LTM Mar 2026$23.2M -21.1%-29.9%2.8%
FLGTFulgent Genetics, Inc.LTM Mar 2026$23.06M -43.7%+6.3%7.2%
BLLNBillionToOne, Inc.LTM Jun 2026$12.18M ——3.1%
PSNLPersonalis, Inc.LTM Mar 2026$5.19M +29.3%-55.1%8.0%
GRALGRAIL, Inc.LTM Jun 2026$504K -70.4%-65.9%0.3%
BDSXBiodesix, Inc.LTM Mar 2026$411K -87.6%-51.5%0.4%
Peer median (excluding GH) $23.06M-16.3%-17.1%3.8%

Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(384.77M)(654.59M)(479.45M)(436.37M)(416.28M)
Depreciation & Amortization22.27M35.96M42.88M42.39M39.74M
Deferred Income Tax00000
Stock-Based Compensation151.45M94.69M90.76M140.41M166.22M
Change in Working Capital(40.47M)61.56M53.84M(60.86M)(14.43M)
Accounts Receivables(44.35M)375K8.38M(21.39M)(28.18M)
Inventory(7.96M)(20.93M)(10.35M)(9.14M)(14.79M)
Accounts Payables8.64M60.33M000
Other Working Capital3.2M21.79M55.81M(30.34M)28.54M
Other Non-Cash Items42.5M152.91M(33.01M)74.58M39.99M
Operating Cash Flow(209.02M)(309.46M)(324.98M)(239.86M)(184.76M)
Capital Expenditures(75.04M)(77.46M)(20.49M)(35.09M)(48.31M)
Acquisitions (Net)0000(58.99M)
Purchases of Investments(940.23M)(327.72M)(635.5M)(314.82M)(827.23M)
Sales of Investments952.11M555M1.5B88.6M307.32M
Other Investing Activities00000
Investing Cash Flow(63.16M)149.82M840.25M(261.31M)(627.2M)
Debt Repayment(146K)(71K)00402.5M
Common Stock Issued00493.12M14.84M377.81M
Common Stock Repurchased0000(45.01M)
Dividends Paid00000
Other Financing Activities(66.68M)(189.02M)(15.74M)(15.83M)(64.17M)
Financing Cash Flow(66.82M)(189.09M)477.38M(996K)671.13M
Effect of Forex Changes(1.69M)(1.6M)(911K)(1.77M)491K
Net Change in Cash(340.69M)(350.34M)991.74M(503.93M)(140.34M)
Free Cash Flow(284.05M)(386.92M)(345.46M)(274.94M)(233.07M)

Guardant Health, Inc.

NASDAQ:GH

Intrinsic Alpha fair value

Locked

Current Price

$145.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.